Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells

Related Experiment Video

Updated: Oct 29, 2026

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

W B Parker1, P W Allan, S C Shaddix

  • 1Southern Research Institute, Birmingham, AL 35205, USA. Parker@SRI.ORG

Biochemical Pharmacology
|June 20, 1998
PubMed

Insights

This study explores novel cancer suicide gene therapy using Escherichia coli purine nucleoside phosphorylase (PNP) to activate toxic purine analogs. These analogs, 2-fluoroadenine (F-Ade) and 6-methylpurine (MeP), show potent, distinct mechanisms against cancer cells.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Suicide gene therapy for cancer shows promise.
  • Activation of purine nucleoside analogs by Escherichia coli purine nucleoside phosphorylase (PNP) is a potential strategy.
  • Mechanisms of toxic purine bases 6-methylpurine (MeP) and 2-fluoroadenine (F-Ade) are not well understood.

Purpose of the Study:

  • To investigate the mechanisms of action of F-Ade and MeP.
  • To compare their efficacy and toxicity with existing anticancer agents.
  • To evaluate their potential in cancer suicide gene therapy.

Main Methods:

  • Cell viability assays (CEM, MRC-5, Balb 3T3 cells) with F-Ade, MeP, and 5-fluorouracil.
  • Measurement of protein, RNA, and DNA synthesis inhibition.
  • Intracellular conversion of F-Ade and MeP to phosphorylated forms (F-ATP, MeP-R-TP).
  • Analysis of F-ATP, MeP-R-TP, and ATP half-lives.
  • Assessment of MeP and F-Ade incorporation into cellular RNA and DNA.

Main Results:

  • F-Ade and MeP demonstrated significantly higher potency (lower IC50 values) than 5-fluorouracil in inhibiting CEM cell growth.
  • Both F-Ade and MeP were toxic to proliferating and quiescent cells.
  • Treatment with F-Ade or MeP inhibited protein, RNA, and DNA synthesis.
  • CEM cells converted F-Ade to F-ATP and MeP to MeP-R-TP.
  • MeP-R-TP had a longer cellular half-life (approx. 48 hr) compared to F-ATP and ATP (approx. 5 hr).
  • Both F-Ade and MeP were incorporated into cellular RNA and DNA.

Conclusions:

  • F-Ade and MeP exhibit distinct mechanisms of action compared to other anticancer agents.
  • Their generation by E. coli PNP offers potential advantages for cancer suicide gene therapy.
  • These advantages include potent toxicity to both proliferating and non-proliferating tumor cells via a novel mechanism.
  • The high potency during short-term treatment is a key benefit.

More Related Videos

Dot Blot Assay for Detecting Global N6-Methyladenosine RNA Modification Levels08:40

Dot Blot Assay for Detecting Global N6-Methyladenosine RNA Modification Levels

Published on: February 6, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Related Concept Videos

Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...